Annual EBITDA
-$158.85 M
+$104.12 M+39.59%
31 December 2023
Summary:
Intra-Cellular Therapies annual earnings before interest, taxes, depreciation & amortization is currently -$158.85 million, with the most recent change of +$104.12 million (+39.59%) on 31 December 2023. During the last 3 years, it has risen by +$71.85 million (+31.14%). ITCI annual EBITDA is now -873.56% below its all-time high of -$16.32 million, reached on 31 December 2012.ITCI EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBITDA
-$38.71 M
-$11.12 M-40.29%
30 September 2024
Summary:
Intra-Cellular Therapies quarterly earnings before interest, taxes, depreciation & amortization is currently -$38.71 million, with the most recent change of -$11.12 million (-40.29%) on 30 September 2024. Over the past year, it has dropped by -$9.13 million (-30.88%). ITCI quarterly EBITDA is now -358335.19% below its all-time high of -$10.80 thousand, reached on 30 June 2013.ITCI Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBITDA
-$121.09 M
-$9.13 M-8.16%
30 September 2024
Summary:
Intra-Cellular Therapies TTM earnings before interest, taxes, depreciation & amortization is currently -$121.09 million, with the most recent change of -$9.13 million (-8.16%) on 30 September 2024. Over the past year, it has increased by +$51.08 million (+29.67%). ITCI TTM EBITDA is now -1121066.67% below its all-time high of -$10.80 thousand, reached on 30 June 2013.ITCI TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ITCI EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +39.6% | -30.9% | +29.7% |
| 3 y3 years | +31.1% | +49.9% | +53.5% |
| 5 y5 years | +1.9% | -6.8% | +21.6% |
ITCI EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +44.3% | -85.9% | +55.9% | -8.2% | +62.5% |
| 5 y | 5 years | -3.5% | +44.3% | -85.9% | +55.9% | -8.2% | +62.5% |
| alltime | all time | -873.6% | +44.3% | <-9999.0% | +55.9% | <-9999.0% | +62.5% |
Intra-Cellular Therapies EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$38.71 M(+40.3%) | -$121.09 M(+8.2%) |
| June 2024 | - | -$27.59 M(+32.5%) | -$111.95 M(-14.8%) |
| Mar 2024 | - | -$20.82 M(-38.7%) | -$131.41 M(-17.3%) |
| Dec 2023 | -$158.85 M(-39.6%) | -$33.96 M(+14.8%) | -$158.85 M(-7.7%) |
| Sept 2023 | - | -$29.58 M(-37.1%) | -$172.16 M(-13.1%) |
| June 2023 | - | -$47.06 M(-2.5%) | -$198.04 M(-17.0%) |
| Mar 2023 | - | -$48.26 M(+2.1%) | -$238.74 M(-9.2%) |
| Dec 2022 | -$262.97 M(-7.8%) | -$47.27 M(-14.8%) | -$262.97 M(-12.8%) |
| Sept 2022 | - | -$55.46 M(-36.8%) | -$301.56 M(-6.7%) |
| June 2022 | - | -$87.75 M(+21.1%) | -$323.29 M(+6.2%) |
| Mar 2022 | - | -$72.49 M(-15.6%) | -$304.55 M(+6.8%) |
| Dec 2021 | -$285.15 M(+23.6%) | -$85.86 M(+11.2%) | -$285.15 M(+9.5%) |
| Sept 2021 | - | -$77.19 M(+11.8%) | -$260.50 M(+8.9%) |
| June 2021 | - | -$69.02 M(+30.0%) | -$239.13 M(+1.8%) |
| Mar 2021 | - | -$53.09 M(-13.3%) | -$234.86 M(+1.8%) |
| Dec 2020 | -$230.70 M(+50.3%) | -$61.21 M(+9.7%) | -$230.70 M(+9.3%) |
| Sept 2020 | - | -$55.82 M(-13.8%) | -$211.12 M(+10.2%) |
| June 2020 | - | -$64.74 M(+32.3%) | -$191.55 M(+15.5%) |
| Mar 2020 | - | -$48.94 M(+17.6%) | -$165.88 M(+8.0%) |
| Dec 2019 | -$153.53 M(-5.2%) | -$41.63 M(+14.8%) | -$153.53 M(-0.6%) |
| Sept 2019 | - | -$36.25 M(-7.2%) | -$154.44 M(-4.4%) |
| June 2019 | - | -$39.07 M(+6.8%) | -$161.48 M(-0.0%) |
| Mar 2019 | - | -$36.59 M(-14.0%) | -$161.49 M(-0.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2018 | -$161.90 M(+58.1%) | -$42.53 M(-1.8%) | -$161.90 M(+6.7%) |
| Sept 2018 | - | -$43.30 M(+10.8%) | -$151.77 M(+14.8%) |
| June 2018 | - | -$39.07 M(+5.6%) | -$132.18 M(+18.4%) |
| Mar 2018 | - | -$37.00 M(+14.2%) | -$111.68 M(+9.1%) |
| Dec 2017 | -$102.38 M(-11.1%) | -$32.40 M(+36.7%) | -$102.38 M(+5.4%) |
| Sept 2017 | - | -$23.71 M(+27.7%) | -$97.15 M(-5.5%) |
| June 2017 | - | -$18.57 M(-33.0%) | -$102.82 M(-11.2%) |
| Mar 2017 | - | -$27.70 M(+1.9%) | -$115.75 M(-0.6%) |
| Dec 2016 | -$115.13 M(+10.0%) | -$27.18 M(-7.5%) | -$116.49 M(-1.4%) |
| Sept 2016 | - | -$29.37 M(-6.7%) | -$118.10 M(-2.3%) |
| June 2016 | - | -$31.50 M(+10.7%) | -$120.85 M(+8.9%) |
| Mar 2016 | - | -$28.45 M(-1.2%) | -$111.01 M(+5.8%) |
| Dec 2015 | -$104.65 M(+241.4%) | -$28.79 M(-10.4%) | -$104.95 M(+14.9%) |
| Sept 2015 | - | -$32.12 M(+48.3%) | -$91.35 M(+39.2%) |
| June 2015 | - | -$21.66 M(-3.2%) | -$65.64 M(+35.3%) |
| Mar 2015 | - | -$22.39 M(+47.4%) | -$48.51 M(+58.2%) |
| Dec 2014 | -$30.66 M(+17.0%) | -$15.19 M(+137.0%) | -$30.66 M(+30.6%) |
| Sept 2014 | - | -$6.41 M(+41.6%) | -$23.47 M(+7.5%) |
| June 2014 | - | -$4.53 M(-0.2%) | -$21.84 M(+26.0%) |
| Mar 2014 | - | -$4.53 M(-43.4%) | -$17.33 M(+35.4%) |
| Dec 2013 | -$26.21 M(+60.7%) | -$8.01 M(+67.5%) | -$12.80 M(+167.2%) |
| Sept 2013 | - | -$4.78 M(>+9900.0%) | -$4.79 M(>+9900.0%) |
| June 2013 | - | -$10.80 K | -$10.80 K |
| Dec 2012 | -$16.32 M | - | - |
FAQ
- What is Intra-Cellular Therapies annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for Intra-Cellular Therapies?
- What is Intra-Cellular Therapies annual EBITDA year-on-year change?
- What is Intra-Cellular Therapies quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for Intra-Cellular Therapies?
- What is Intra-Cellular Therapies quarterly EBITDA year-on-year change?
- What is Intra-Cellular Therapies TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for Intra-Cellular Therapies?
- What is Intra-Cellular Therapies TTM EBITDA year-on-year change?
What is Intra-Cellular Therapies annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of ITCI is -$158.85 M
What is the all time high annual EBITDA for Intra-Cellular Therapies?
Intra-Cellular Therapies all-time high annual earnings before interest, taxes, depreciation & amortization is -$16.32 M
What is Intra-Cellular Therapies annual EBITDA year-on-year change?
Over the past year, ITCI annual earnings before interest, taxes, depreciation & amortization has changed by +$104.12 M (+39.59%)
What is Intra-Cellular Therapies quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of ITCI is -$38.71 M
What is the all time high quarterly EBITDA for Intra-Cellular Therapies?
Intra-Cellular Therapies all-time high quarterly earnings before interest, taxes, depreciation & amortization is -$10.80 K
What is Intra-Cellular Therapies quarterly EBITDA year-on-year change?
Over the past year, ITCI quarterly earnings before interest, taxes, depreciation & amortization has changed by -$9.13 M (-30.88%)
What is Intra-Cellular Therapies TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of ITCI is -$121.09 M
What is the all time high TTM EBITDA for Intra-Cellular Therapies?
Intra-Cellular Therapies all-time high TTM earnings before interest, taxes, depreciation & amortization is -$10.80 K
What is Intra-Cellular Therapies TTM EBITDA year-on-year change?
Over the past year, ITCI TTM earnings before interest, taxes, depreciation & amortization has changed by +$51.08 M (+29.67%)